Biotech

All Articles

Lilly posts more good records on its own every week blood insulin prospect

.On the heels of an FDA turndown for its chief rival Novo Nordisk, Eli Lilly is making headway in th...

IN 8bio halts stage 2 test, lays off fifty percent of labor force

.Merely a few months after application the initial person in a stage 2 trial for freshly detected gl...

Lilly, Haya ink $1B biobuck being overweight contract to explore darker genome

.Eli Lilly's hunt for weight problems aim ats has actually led it to the black genome. The Big Pharm...

ArsenalBio elevates $325M, rotates away from previous lead possession

.Collection Biosciences is carrying on up. The cell therapy firm has actually added on $325 million ...

Lilly- supported weight reduction biotech data IPO

.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has submitte...

Aelis' cannabis make use of drug fails stage 2b, driving Indivior to review $100M option

.Aelis Farma's hopes of protecting an easy, positive decision on a $one hundred million alternative ...

ProKidney halts phase 3 trial certainly not required for tissue treatment confirmation

.ProKidney has quit some of a pair of phase 3 trials for its own cell therapy for kidney condition a...

Vaxcyte surges on 'spectacular' 31-valent PCV win versus Pfizer

.Vaxcyte unveiled what analysts called "stunning" stage 1/2 data for its own 31-valent pneumococcal ...

Recursion's mind health condition test presents little proof of efficacy

.Recursion has discovered through a very early examination of its tech-enabled approach to drug reve...

Acepodia, Pfizer click on with each other for chemistry-based cell therapy

.Call it a scenario of really good chemistry: Acepodia, a biotech based upon Nobel Champion scientif...